【摘要】 目的 探讨恩替卡韦治疗慢性乙型肝炎合并2型糖尿病疗效及肾脏安全性研究。方法 选取2021年2月-2023年2月本院收治的72例慢性乙型肝炎合并2型糖尿病患者，分为2组。对照组用富马酸替诺福韦酯治疗，研究组用恩替卡韦治疗。观察分析2组临床疗效、肾功能、糖脂代谢、肝功能等情况。结果 与对照组比，研究组临床疗效好、SCr及BUN水平低、eGFR水平高、FBG、HbA1c水平低、ALT、AST和TBIL水平低，差异均有统计学意义(P<0.05)。结论 患者采用恩替卡韦治疗能够取得较为理想的抗病毒治疗效果，对肾脏具有较高的安全性，值得应用。更多还原

【Abstract】 Objective To investigate the efficacy and renal safety of entecavir in the treatment of chronic hepatitis B(CHB)complicated with type 2 diabetes mellitus(T2DM). Methods A total of 72 patients with CHB complicated with T2DM admitted to our hospital from February 2021 to February 2023 were divided into two groups. The control group was treated with tenofovir fumarate, and the study group was treated with entecavir. Clinical efficacy, renal function, glucose and lipid metabolism and liver function of the two groups were observed and analyzed. Results Compared with the control group, the clinical effect of the study group was better, SCr and BUN levels were lower, eGFR levels were higher, FBG and HbA1c levels were lower, ALT,AST and TBIL levels were lower, and the differences were statistically significant(P<0.05). Conclusions Patients treated with entecavir can achieve a relatively ideal antiviral treatment effect, and has a high safety on the kidney, which is worthy of application.更多还原